For the fourth consecutive year, the Iker Association donated to myxoid liposarcoma research at VHIO. This association aims to promote…
César Serrano
The pivotal phase 3 MANEUVER trial is a three-part, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety…
Co-authored by César Serrano, a Medical Oncologist at the Vall d’Hebron University Hospital and Head of VHIO’s Sarcoma Translational Research…
Today, February 29th is celebrated World Rare Disease Day with the aim of raising awareness in society about these pathologies…
Recently published in the journal Nature Medicine (1), results of exploratory research from the open-label phase III INTRIGUE clinical trial…
Blood-based circulating tumor DNA analysis of plasma samples from patients enrolled in the open-label, randomized phase III VOYAGER clinical trial…
Led by VHIO’s César Serrano, alongside first author Jonathan C. Trent at the Sylvester Comprehensive Cancer Center in Miami, an…
After an initial response to approved tyrosine kinase inhibitors, principally imatinib, most patients with GIST will develop acquired cancer drug…
In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core…
